Researchers observed that only 8.3% of 24 children or adolescents with peanut allergy passed a double-blind placebo-controlled food challenge with at least 444 mg of peanut protein after receiving ...

The following is a summary of “Longitudinal integrated proteomic and metabolomic skin changes in atopic dermatitis patients ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.

More information: Mark Boguniewicz et al, Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities, Advances in Therapy (2024). DOI: 10.1007/s12325-024 ...

KT-621 is an investigational first-in-class once-daily, oral STAT6 degrader with dupilumab-like activity in preclinical models and the potential to address multiple allergic and atopic diseases ...

Medicare covers medically necessary treatment for eczema. This includes medicated creams and pills, dupilumab (Dupixent) injections, and phototherapy. Original Medicare with a Part D plan or an ...

Further information NICE will not progress with an appraisal for this indication due to positive guidance in the adult population within TA534. NHS England and Improvement will commission treatments ...